| Pharmaceutical Information |
| Drug Name |
Glucarpidase |
| Drug ID |
BADD_D01028 |
| Description |
Glucarpidase is the recombinant form of the Pseudomonas sp. (strain RS-16) enzyme carboxypeptidase G2 that is produced in Escherichia coli. In patients, glucarpidase inactivates methotrexate, and other antifolates, by hydrolyzing glutamate on the carboxyl terminal of these compounds. Therefore since methotrexate is eliminated enzymatically and not by the kidneys, glucarpidase is indicated in patients on methotrexate treatment who have kidney dysfunction, and are experiencing an abnormally high plasma concentration of methotrexate (>1 micromole per liter). Glucarpidase is marketed under the brand name Voraxaze®. |
| Indications and Usage |
Used in patients on methotrexate treatment who have kidney dysfunction, and are experiencing an abnormally high plasma concentration of methotrexate (> 1 micromole per liter). |
| Marketing Status |
approved; investigational |
| ATC Code |
V03AF09 |
| DrugBank ID |
DB08898
|
| KEGG ID |
D10260
|
| MeSH ID |
C000629556
|
| PubChem ID |
21195079
|
| TTD Drug ID |
D0P4PZ
|
| NDC Product Code |
50633-210; 76356-101 |
| UNII |
2GFP9BJD79
|
| Synonyms |
glucarpidase | Voraxaze |
|
| Chemical Information |
| Molecular Formula |
Zn4+8 |
| CAS Registry Number |
9074-87-7 |
| SMILES |
[Zn+2].[Zn+2].[Zn+2].[Zn+2] |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
